Solexa Narrows 3Q Loss
13th Nov 2006, 22:53 GMT
Biotech company Solexa said its Q3 loss narrowed as a tax benefit offset a drop in revenue and an increase in expenses.
Solexa Narrows 3Q Loss related news:
- Targacept narrows 3Q loss — Latest news from The Business Journal of the Greater Triad Area
- Solexa posts narrowed Q3 loss — Latest news from East Bay Business Times
- Muzak narrows 3Q loss, names CFO — Latest news from Charlotte Business Journal
- Taleo narrows Q3 loss — bizjournals.com Banking & Financial Services:Commercial Banking headlines
- Micrus narrows Q2 loss on 137% revenue jump — Latest news from Silicon Valley/San Jose Business Journal
- PokerTek posts 3Q loss of $2.3M — Latest news from Charlotte Business Journal
- Illumina Acquires Solexa — socalTECH.com - Southern California High Tech News
- Illumina to Buy Solexa for $600 Million — WSJ.com: US Business
- Regency posts larger 3Q loss — Latest news from Dallas Business Journal
- Iomai 3Q Loss Widens — StratWire - Business of Healthcare NewsFeed
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress